Kailera Therapeutics (KLRA)
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops...
- Open
- 18.200
- High
- 18.372
- Low
- 17.170
- Prev. Close
- 18.320
- Volume
- 544.93K
- Turnover
- 9.52M
- Avg Price
- 17.475
- Bid/Ask Ratio
- 98.02%
- Amplitude
- 6.56%
- 52wk High
- 28.227
- Volume Ratio
- 0.93
- Turnover Ratio
- 0.93%
Kailera Therapeutics Analyst Rating
View moreForecast & Rating
Aug 13, 2026Price forecast
$42.40142.84%
Forecast & RatingStrong buy
6analysts
- Strong buy83.33%
- Buy16.67%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- prnewswire · 2 days ago, 06:48 AM
07:46 ETHengrui Pharma Reports 2026 Interim Results as Innovation and Globalization Continue to Drive Business Momentum
- MSN · 2 days ago, 09:24 AM
Kailera Therapeutics: The record-breaking obesity IPO big pharma cannot ignore
- Market Beat · Aug 17 at 12:40 PM
Kailera Therapeutics (NASDAQ:KLRA) Trading 6.6% Higher - Here's Why
- Motley Fool · Aug 16 at 03:11 PM
2 GLP-1 Stocks That Could Double Your Money by 2031
- Earnings Watch · Aug 12 at 03:58 PM
Kailera Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0
- PUBT · Aug 12 at 03:05 PM
Kailera Q2 FY26 net loss widens to $111.31 million; R&D expenses climb to $101.06 million
